Free tool
FAERS Monitor: Acular Ls
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021528 or its brand name (Acular Ls, Ketorolac Tromethamine). Reports on generic versions are filed under their own applications.
Reports
4,453
Serious
2,549
57% of reports
Hospitalization
1,288
Death reported
258
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective491
- drug hypersensitivity300
- nausea255
- headache248
- pain241
- dyspnoea227
- fatigue219
- treatment failure207
- off label use163
- vomiting161
- diarrhoea150
- product dose omission issue146
- dizziness126
- eye pain125
- back pain124
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 43 |
| 2005 | 71 |
| 2006 | 70 |
| 2007 | 69 |
| 2008 | 91 |
| 2009 | 106 |
| 2010 | 109 |
| 2011 | 162 |
| 2012 | 195 |
| 2013 | 69 |
| 2014 | 83 |
| 2015 | 103 |
| 2016 | 314 |
| 2017 | 224 |
| 2018 | 200 |
| 2019 | 276 |
| 2020 | 461 |
| 2021 | 222 |
| 2022 | 299 |
| 2023 | 363 |
| 2024 | 339 |
| 2025 | 337 |
| 2026 | 247 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,706 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment failureSignal | 207 | 11.8 | 10.4 | 2,044 |
| eye painSignal | 125 | 10.5 | 8.8 | 1,064 |
| drug hypersensitivitySignal | 300 | 7.3 | 6.6 | 1,647 |
| back painSignal | 124 | 2.5 | 2.1 | 114 |
| product dose omission issueSignal | 146 | 2.3 | 2.0 | 113 |
| dyspnoea | 227 | 1.9 | 1.7 | 98 |
| headache | 248 | 1.9 | 1.7 | 102 |
| pain | 241 | 1.9 | 1.6 | 97 |
| drug ineffective | 491 | 1.8 | 1.6 | 171 |
| vomiting | 161 | 1.6 | 1.4 | 38 |
| nausea | 255 | 1.5 | 1.4 | 47 |
| fatigue | 219 | 1.3 | 1.2 | 18 |
| dizziness | 126 | 1.2 | 1.0 | 4 |
| diarrhoea | 150 | 1.1 | 0.9 | 1 |
| off label use | 163 | 0.9 | 0.8 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.